← All trials
NCT04321278
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 28, 2020
- Primary completion
- Aug 30, 2020
- Completion date
- Aug 30, 2020
- First posted
- Mar 25, 2020
- Last posted
- Apr 1, 2020
- Enrollment
- 440
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Albert Einstein Israelite HospitalLead sponsor
- Hospital Sirio-LibanesCollaborator
- Brazilian Research In Intensive Care NetworkCollaborator
- EMS S/ACollaborator
- Cristália Produtos Químicos Farmacêuticos Ltda.Collaborator
- Albert Einstein Israelite HospitalStudy director
- Hospital do CoracaoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.